Last, we explored whether there were differences in cognitive impairment between patients receiving basic therapy (interferon beta, glatirameracetate) or no therapy (N = 33 in total) and patients receiving escalation therapy (natalizumab, fingolimod; N = 7). Here, IFNB1 is linked to Cognitive impairment.